Immune Mediated Necrotizing Myopathy: Where do we Stand?

Author(s): Abdel Gaffar A Mohammed*, Ayanda Gcelu, Farzana Moosajee, Stella Botha, Asgar Ali Kalla

Journal Name: Current Rheumatology Reviews

Volume 15 , Issue 1 , 2019

Become EABM
Become Reviewer

Abstract:

Immune-mediated necrotizing myopathies (IMNMs) are a group of acquired autoimmune muscle disorders which are characterized by proximal muscle weakness, high levels of creatinine kinase, and myopathic findings on electromyogram (EMG). Muscle biopsy in IMNM differentiates it from the other subgroups of Idiopathic Inflammatory Myositis (IIM) by the presence of myofibre necrosis and prominent regeneration without substantial lymphocytic inflammatory infiltrates. Anti-signal recognition particle (SRP) and anti-3hydroxy-3 methylglutarylcoenzyme A reductase (HMGCR) autoantibodies were found in two-thirds of IMNM patients. In terms of treatment, IMNM is more resistant to conventional immunosuppressive treatment, therefore, other modalities of treatment such as Intravenous Immunoglobulin (IVIG) and rituximab are often required.

Keywords: Myopathy, anti-SRP, myositis, anti-HMGCR, IMNMs, EMG, IVIG.

[1]
Christopher‐Stine L, Casciola‐Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200‐kd and 100‐kd proteins is associated with an immune‐mediated necrotizing myopathy. Arthritis Rheum 2010; 62(9): 2757-66.
[2]
Hengstman GJ, Ter Laak HJ, Egberts WV, et al. Anti-signal recognition particle autoantibodies: Marker of a necrotising myopathy. Ann Rheum Dis 2006; 65(12): 1635-8.
[3]
Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol 2011; 23(6): 612-9.
[4]
Singh JA, Saag KG, Bridges Jr SL, et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016; 68(1): 1-26.
[5]
Ohnuki Y, Suzuki S, Shiina T, et al. HLA-DRB1 alleles in immune-mediated necrotizing myopathy. Neurology 2016; 31: 10-212.
[6]
Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2015; 2(4): e124.
[7]
Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in european patients with autoimmune necrotizing myopathies: Inconstant exposure to statin. Medicine 2014; 93(3): 150-7.
[8]
Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: Clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73(4): 420-8.
[9]
Watanabe Y, Akinori U, Shigeaki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 2016; 87(10): 1038-44.
[10]
Chung T, Christopher‐Stine L, Paik JJ, Corse A, Mammen AL. The composition of cellular infiltrates in anti‐HMG‐CoA reductase‐associated myopathy. Muscle Nerve 2015; 52(2): 189-95.
[11]
Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63(7): 1961-71.
[12]
Dalakas MC. Inflammatory muscle diseases inflammatory muscle diseases. N Engl J Med 2015; 372(18): 1734-47.
[13]
Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol 2015; 72(9): 996-1003.
[14]
Benveniste O, Romero NB. Myositis or dystrophy? Traps and pitfalls. Presse Med 2011; 40(4): e249-55.
[15]
Bangert E, Afanasyeva M, Lach B, et al. Takotsubo cardiomyopathy in the setting of necrotizing myopathy. Int J Cardiol 2014; 174(2): e21-3.
[16]
Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: Usefulness of myositis specific antibody. Brain 2016; 139(8): 2131-5.
[17]
Sugie K, Eura N, Kobayashi Y, Sawa N, Ueno S. Clinicopathological and neuroradiological features of myopathy associated with antibodies to signal recognition particle (SRP). Eur J Int Med 2013; 24: e120.
[18]
Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: Case series of 100 patients. Orphanet J Rare Dis 2015; 10(1): 61.
[19]
Takada T, Hirakata M, Suwa A, et al. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod Rheumatol 2009; 19(2): 156-64.
[20]
Wang L, Liu L, Hao H, et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 2014; 24(4): 335-41.
[21]
Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: Clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73(4): 420-8.
[22]
Mammen AL, Chung T, Christopher‐Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63(3): 713-21.
[23]
Ramanathan S, Langguth D, Hardy TA, et al. Clinical course and treatment of anti-HMGCR antibody–associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm 2015; 2(3): e96.
[24]
Grable‐Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune‐mediated necrotizing myopathy associated with statins. Muscle & Nerve 2010; 41(2): 185-90.
[25]
Dalakas MC. An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011; 37(3): 226-42.
[26]
Luo YB, Mastaglia FL. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies. Biochim Biophys Acta 2015; 1852(4): 622-32.
[27]
Ernste FC, Reed AM. Idiopathic inflammatory myopathies: Current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013; 88: 83-105.
[28]
Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011; 305(2): 183-90.
[29]
Zheng Y, Liu L, Wang L, et al. Magnetic resonance imaging changes of thigh muscles in myopathy with antibodies to signal recognition particle. Rheumatol 2014; 54(6): 1017-24.
[30]
Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: Extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 2017; 76(4): 681-7.
[31]
Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: Update on diagnosis and management. Curr Rheumatol Rep 2015; 17(12): 72.
[32]
Quinn C, Salameh JS, Smith T, Souayah N. Necrotizing myopathies: An update. J Clin Neuromuscul Dis 2015; 16(3): 131-40.
[33]
Christopher-Stine. Khan S, Inflammatory muscle diseases. Clin Immunol Princ Pract Fourth Ed 2012; pp. 667-75. 2012.
[34]
Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med 2016; 374(7): 664-9.
[35]
Pinal‐Fernandez I, Parks C, Werner JL, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res 2017; 69(2): 263-70.
[36]
Ashton C, Junckerstorff R, Bundell C, Hollingsworth P, Needham M. Treatment and outcomes in necrotising autoimmune myopathy: an Australian perspective. Neuromuscul Disord 2016; 26(11): 734-40.
[37]
Dalakas MC. Immunotherapy of myositis: Issues, concerns and future prospects. Nat Rev Rheumatol 2010; 6(3): 129.
[38]
Curtin D, Costigan D, McCarthy C, et al. Novel antibody associations in immune-mediated necrotising myopathy without inflammation. Ir J Med Sci 2016; 185(4): 941-3.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2019
Page: [23 - 26]
Pages: 4
DOI: 10.2174/1573397114666180406101850
Price: $65

Article Metrics

PDF: 79
HTML: 10